514. Association Between Antibiotic Exposure and Clinical Outcomes of Immune Checkpoint Inhibition
G. W. Wilson(University of Massachusetts Amherst), Fyza Y. Shaikh(Johns Hopkins University), Jessica Queen(Johns Hopkins University), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Emma Spence(Johns Hopkins University), Jiajia Zhang(Bloomberg (United States)), Christopher Fan(Johns Hopkins University), Cynthia L. Sears(Johns Hopkins University), Jawara Allen(Johns Hopkins University), Maxwell White(Johns Hopkins University)
Cited by 1
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
|Cancer Discovery|2014|1.5k
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
|Cancer Discovery|2016|897
Microbes, Microbiota, and Colon Cancer
|Cell Host & Microbe|2014|818